Digestive Health Newsletter

Fertility, Pregnancy, and Breastfeeding with Inflammatory Bowel Disease (IBD)

Uma Mahadevan, MD

Volume 26, 
May 01, 2011

by Uma Mahadevan, MD

Uma Mahadevan Uma Mahadevan, MD, is an Associate Professor of Medicine at the University of California, San Francisco (UCSF) and Director of Clinical Research at the UCSF Center for Colitis and Crohn's Disease. She specializes in the treatment of IBD, with a particular interest in pregnancy and fertility in IBD, as well as in clinical trials of experimental drug therapy. Dr. Mahadevan’s current projects include pregnancy outcomes in women with IBD, clinical trials in biologic therapy for IBD, and the effects of IBD medications on male fertility and semen integrity.


Table of Contents


Introduction

If you have inflammatory bowel disease (IBD) and are thinking about starting a family, you may wonder how your chronic illness and the medication you take can affect fertility, pregnancy, childbirth, and breastfeeding. The good news is that most people with IBD have normal fertility, and most women with IBD can expect a normal pregnancy and delivery, as well as a healthy baby. This newsletter will answer some of the more common questions you may have.

Back to Top

Will IBD affect my fertility?

In general, neither men nor women with IBD have decreased fertility when compared to the general population, however there are several exceptions.

If you are a woman . . .

  • Pelvic surgery to manage your IBD can result in scar tissue, making it difficult for you to conceive.
  • IBD can increase your risk of precancerous cervical cells (especially if you are taking immunosuppressants or biologics), which can decrease your fertility.
  • You may have irregular periods during flares, which can make it difficult to conceive.

If you are a man . . .

  • Taking sulfasalazine can affect sperm count and quality, so be sure to talk to your physician about switching to a different medication several months prior to trying to conceive.

Back to Top

Can I have a healthy pregnancy, even though I have IBD?

If your IBD is in remission, you are likely to have a healthy pregnancy, although your chance of complications – for example, miscarriage, premature delivery, or a low birth weight baby – is somewhat increased. Therefore, it is important that your obstetrician follows you as a high-risk patient.

Back to Top

What steps can I take before conceiving to promote a healthy pregnancy?

The sooner any woman sets the stage for a healthy pregnancy, the better the odds. For example, all women considering pregnancy should eat a healthy diet and not smoke or drink alcohol. If you have IBD, it is also important to be in remission when you conceive and to ensure that your gastroenterologist and obstetrician work together as a team. You should have a plan in place prior to conception regarding the medications you can take during pregnancy and breastfeeding. Also confirm that you are up to date for all immunizations, a pap smear, and surveillance colonoscopy. If you are between the ages of 9 and 26, you may want to consider the human papillomavirus (HPV) vaccine, which protects against the infection that can lead to cervical cancer, especially if you have taken immunosuppressants or biologic therapy. Finally, be sure to have your B12, folate, and vitamin D levels checked, and take supplements if you need them.

Back to Top

Are there specific foods I should eat for a healthy pregnancy?

When it comes to nutrition, the ideal goal for a healthy pregnancy is a balanced diet that includes fortified breads and cereals, vegetables, fruits, low-fat dairy products, and lean meat, chicken, fish and shellfish (be sure to choose types that are low in mercury, like shrimp, canned light tuna, salmon, pollock, and catfish).

The USDA’s “Daily Food Plan for Moms” can help you determine what and how much you need to eat, based on your age, weight, trimester, and other factors. Keep in mind that some foods may cause morning sickness or trigger your symptoms, so you might need to adjust your diet accordingly.

Finally, be sure to drink enough fluids. Pregnancy can increase the diarrhea that typically accompanies IBD, making adequate hydration even more important than usual.

Back to Top

Does IBD make it more likely that I will have a flare during pregnancy?

Pregnancy has no impact on the likelihood of flares. In fact, some women with IBD report that their disease is less active during pregnancy.

Back to Top

Is it true that IBD can increase my risk of hemorrhoids during pregnancy?

Diarrhea or constipation, which are common IBD symptoms, can increase the likelihood that you will have hemorrhoids during your pregnancy. To ease hemorrhoid discomfort, try soaking in warm water several times each day or applying ice packs or cold compresses to ease swelling. It also helps to avoid sitting for prolonged periods and to keep the anal area clean.

Back to Top

Can I have a vaginal delivery, even though I have IBD?

Most women with IBD can have a normal, vaginal delivery. You might have heard about an increased rate of cesarean sections in women with IBD, but this is most likely due to patient or physician preference, and is not related to medical need.

You may need a cesarean section if you have active perianal disease, which can be aggravated by a vaginal delivery, or if you have an ileoanal pouch, since a vaginal delivery can damage the anal sphincter. Scarring in the perineum or rectum may also result in the need for a cesarean section, because it can impede the stretching required to accommodate your baby’s head during delivery.

Back to Top

What if I need gastrointestinal surgery while I’m pregnant?

If you have IBD-related complications during your pregnancy, always consider non-surgical treatment first. If non-surgical treatment is not an option or is unsuccessful, surgery is typically well-tolerated, especially during the second trimester.

Back to Top

What if I need a gastrointestinal diagnostic procedure while I’m pregnant?

There is no need for routine diagnostic procedures during pregnancy, however most procedures, including colonoscopy, sigmoidoscopy, upper endoscopy, and MRI , can be safely performed, if necessary. Exceptions include CT scans and standard X-rays, which should be ordered only in a medical emergency.

Back to Top

Can I continue taking my IBD medication while I’m pregnant or breastfeeding?

You should always consult with your healthcare professional before starting medications during pregnancy or while breastfeeding. Many IBD medications are considered to be low-risk during pregnancy and compatible for use during breastfeeding. In fact, the risks related to a disease flare during pregnancy (miscarriage, low birth weight, and pre-term birth) are much greater than the risks related to most IBD medications. Therefore, stopping your medications, particularly without the knowledge and consent of your gastroenterologist, may be the biggest risk to your pregnancy. The following table lists common medications and recommendations for pregnancy and breastfeeding.

Back to Top

Conclusion

Years ago, women with IBD were counseled against pregnancy, but that is no longer the case. Thanks to a better understanding of the disease and improved medication to treat it, most women can expect to have normal fertility, a successful pregnancy and delivery, and a healthy baby. If you have IBD and are planning to get pregnant, remember that each person’s disease is different. Be sure to involve your gastroenterologist and obstetrician in any decisions you make, so that you get the best possible support for you and your baby. Remember to tell your pediatrician what medications you took during pregnancy, as this may impact the vaccines given to your baby.

Back to Top


IBD Medication: FDA Recommendations for Pregnancy and Breastfeeding
DRUG US FDA PREGNANCY CATEGORYUS FDA PREG NANCY CATE GORY RECOMMENDATIONS FOR PREGNANCYRECOMMEN DATIONS FOR PREGNANCY RECOMMENDATIONS FOR BREASTFEEDINGRECOMMEN DATIONS FOR BREASTFEEDING
Aminosalicylates
Balsalazide B Low risk Limited human data; probably compatible
Mesalamine (except Asacol) B Low risk Limited human data; probably compatible
Asacol C Low risk; dibutyl phthalate in coating Limited human data; probably compatible
Olsalazine C Low risk Limited human data; probably compatible
Sulfasalazine B Low risk; take 2 mg folate daily Limited human data; probably compatible
Antibiotics
Amoxicillin/ clavulanic acid B Low risk Probably compatible
Quinolones, ciprofloxacin C Avoid Limited human data; avoid prolonged use
Metronidazole B Low risk; avoid 1st trimester Limited human data; potential toxicity
Rifaximin C No human data; causes birth defects in animals No human data
Biologics
Adalimumab B Low risk Limited human data; probably compatible
Certolizumab B Low risk Limited human data; probably compatible
Infliximab B Low risk Limited human data; probably compatible
Natalizumab C Limited human data Limited human data; probably compatible
Corticosteroids
All corticosteroids, including budesonide C Low risk; avoid 1st trimester Compatible
Immunomodulators
Azathioprine/6MP D Causes birth defects in animals when given at high doses; low risk Limited human data; probably compatible
Cyclosporine C Low risk Limited human data; potential toxicity
Methotrexate X Contraindicated Contraindicated
Tacrolimus C Low risk Limited human data; potential toxicity
Thalidomide X Contraindicated Contraindicated

The following FDA categories indicate the potential of a drug to cause birth defects if used during pregnancy.

Category A

Adequate and well-controlled studies have failed to demonstrate a risk to the fetus in the first trimester of pregnancy (and there is no evidence of risk in later trimesters).

Category B

Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women.

Category C

Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Category D

There is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience or studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

Category X

Studies in animals or humans have demonstrated fetal abnormalities and/or there is positive evidence of human fetal risk based on adverse reaction data from investigational or marketing experience, and the risks involved in use of the drug in pregnant women clearly outweigh potential benefits.

Important Safety Information about AZASAN

WARNING: Chronic immunosuppression with this purine antimetabolite increases risk of neoplasia in humans. Physicians using this drug should be very familiar with this risk as well as with the mutagenic potential to both men and women and with possible hematologic toxicities. See WARNINGS section in complete Prescribing Information.

AZASAN® (azathioprine tablets) 75/100 mg is indicated as an adjunct for the prevention of rejection in renal homotransplantations, and also for the management of active rheumatoid arthritis to reduce signs and symptoms.The most commonly reported side effects associated with AZASAN therapy are leukopenia and/or thrombocytopenia, secondary infections, neoplasia, nausea, vomiting, diarrhea, fever, myalgias, skin rashes, and hepatotoxicity. AZASAN therapy should be given cautiously when used concomitantly with allopurinol, ACE inhibitors, and other agents affecting myelopoiesis. AZASAN is contraindicated in pregnant and lactating women and in patients who have shown hypersensitivity to this product.

Consult with your physician to see if this product is right for you.

Complete Prescribing Information for AZASAN, including BOXED WARNINGpdf

Important Safety Information about METOZOLV® ODT

WARNING: TARDIVE DYSKINESIA

See full prescribing information for complete boxed warning.

Treatment with metoclopramide can cause tardive dyskinesia, a serious movement disorder that is often irreversible. The risk of developing tardive dyskinesia increases with the duration of treatment and the total cumulative dose.

Metoclopramide therapy should be discontinued in patients who develop signs or symptoms of tardive dyskinesia. There is no known treatment for tardive dyskinesia. In some patients, symptoms may lessen or resolve after metoclopramide treatment is stopped.

Treatment with metoclopramide for longer than 12 weeks should be avoided in all but rare cases where therapeutic benefit is thought to outweigh the risk of developing tardive dyskinesia.

METOZOLV® ODT (metoclopramide HCl) is indicated as short-term (4 to 12 weeks) therapy for adults with symptomatic, documented gastroesophageal reflux disease (GERD) who fail to respond to conventional therapy and for the relief of symptoms associated with acute and recurrent diabetic gastroparesis (diabetic gastric stasis) in adults. Therapy should not exceed 12 weeks in duration. Take on an empty stomach up to four times daily, at least 30 minutes before eating and at bedtime.

METOZOLV ODT is contraindicated in patients with intestinal obstruction, hemorrhage, or perforation; pheochromocytoma; known sensitivity or intolerance to metoclopramide; epilepsy; or are receiving concomitant medications with extrapyramidal reactions.

Extrapyramidal symptoms (EPS), manifested primarily as acute dystonic reactions, occur in approximately 1 in 500 patients treated with the usual adult dosages of 30 to 40 mg/day of metoclopramide. These usually are seen during the first 24 to 48 hours of treatment with metoclopramide, occur more frequently in pediatric patients and adult patients less than 30 years of age and are even more frequent at higher doses.

Drug-induced Parkinsonism can occur during metoclopramide therapy, more commonly within the first 6 months after beginning treatment, but also after longer periods. Patients with a history of Parkinson’s disease should be given metoclopramide cautiously, if at all, since such patients can experience exacerbation of Parkinsonian symptoms when taking metoclopramide.

There have been rare reports of an uncommon but potentially fatal symptom complex sometimes referred to as Neuroleptic Malignant Syndrome (NMS) associated with metoclopramide. Clinical manifestations of NMS include hyperthermia, muscle rigidity, altered consciousness, and evidence of autonomic instability. The management of NMS should include immediate discontinuation of metoclopramide and other drugs not essential to concurrent therapy.

Depression associated with metoclopramide use has occurred in patients with and without a history of depression. For those patients with a prior history of depression, metoclopramide should only be given if the expected benefits outweigh the potential risks.

In one study in hypertensive patients, intravenously administered metoclopramide was shown to release catecholamines; hence, caution should be exercised when metoclopramide is used in patients with hypertension. Any rapid rise in blood pressure associated with METOZOLV ODT use should result in immediate cessation of metoclopramide use in those patients.

Since metoclopramide produces a transient increase in plasma aldosterone, patients with cirrhosis or congestive heart failure may be at risk of developing fluid retention and volume overload. If these side effects occur at any time in any patients during metoclopramide therapy, the drug should be discontinued.

Adverse reactions, especially those involving the nervous system, may occur after stopping the use of METOZOLV ODT.

In clinical studies, the most frequently reported adverse events (≥2% occurrence) were headache, nausea, fatigue, somnolence, and vomiting.

Complete Prescribing Information for METOZOLV ODT, including BOXED WARNING pdf

Important Safety Information about OSMOPREP

WARNINGS

There have been rare, but serious reports of acute phosphate nephropathy in patients who received oral sodium phosphate products for colon cleansing prior to colonoscopy. Some cases have resulted in permanent impairment of renal function and some patients required long–term dialysis. While some cases have occurred in patients without identifiable risk factors, patients at increased risk of acute phosphate nephropathy may include those with increased age, hypovolemia, increased bowel transit time (such as bowel obstruction), active colitis, or baseline kidney disease, and those using medicines that affect renal perfusion or function (such as diuretics, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], and possibly nonsteroidal anti–inflammatory drugs [NSAIDs]).

It is important to use the dose and dosing regimen as recommended (PM/AM split dose).

OSMOPREP® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. Considerable caution should be advised before OSMOPREP is used in patients with severe renal insufficiency, congestive heart failure, ascites, unstable angina, gastric retention, ileus, severe chronic constipation, bowel perforation, toxic megacolon, gastric bypass or stapling surgery, or hypomotility syndrome. Use with caution in patients with impaired renal function, patients with a history of seizures or at higher risk of seizure, patients with higher risk of cardiac arrhythmias, known or suspected electrolyte disturbances (such as dehydration), or people taking drugs that affect electrolyte levels. Patients with electrolyte abnormalities such as hypernatremia, hyperphosphatemia, hypokalemia, or hypocalcemia should have their electrolytes corrected before treatment with OSMOPREP.

OSMOPREP is contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients, and in patients with biopsy–proven acute phosphate nephropathy. In clinical trials, the most commonly reported adverse reactions (reporting frequency >3%) were abdominal bloating, nausea, abdominal pain, and vomiting. It is recommended that patients receiving OSMOPREP be advised to adequately hydrate before, during, and after the use of OsmoPrep.

For complete Prescribing Information for OSMOPREP including BOXED WARNING.pdf

Important Safety Information about VISICOL

WARNINGS

There have been rare, but serious reports of acute phosphate nephropathy in patients who received oral sodium phosphate products for colon cleansing prior to colonoscopy. Some cases have resulted in permanent impairment of renal function and some patients required long-term dialysis. While some cases have occurred in patients without identifiable risk factors, patients at increased risk of acute phosphate nephropathy may include those with increased age, hypovolemia, increased bowel transit time (such as bowel obstruction), active colitis, or baseline kidney disease, and those using medicines that affect renal perfusion or function (such as diuretics, angiotensin converting enzyme [ACE] inhibitors, angiotensin receptor blockers [ARBs], and possibly nonsteroidal anti-inflammatory drugs [NSAIDs]).

It is important to use the dose and dosing regimen as recommended (PM/AM split dose).

VISICOL® (sodium phosphate monobasic monohydrate, USP, and sodium phosphate dibasic anhydrous, USP) Tablets are indicated for cleansing of the colon as a preparation for colonoscopy in adults 18 years of age or older. VISICOL is not to be used in patients with congestive heart failure, ascites, unstable angina pectoris, gastric retention, ileus or acute obstruction or pseudo-obstruction, severe chronic constipation, bowel perforation, acute colitis, toxic megacolon, or hypomotility syndrome. Use with caution in patients with impaired renal function, pre-existing electrolyte disturbances, or people taking drugs that affect electrolyte levels. VISICOL is contraindicated in patients with a known allergy or hypersensitivity to sodium phosphate salts or any of its ingredients. In clinical trials, the most commonly observed (≥1%) adverse reactions occurring with use of VISICOL were generally transient and self-limited and included nausea, vomiting, abdominal bloating, abdominal pain, dizziness and headache.

Consult with your physician to see if this product is right for you.

Complete Prescribing Information for VISICOL, including BOXED WARNING pdf

The information contained on this page is intended for US patients, healthcare professionals, and pharmacists only.

SWB11/03

Salix Pharmaceuticals on Facebook   Salix Pharmaceuticals on Twitter